Dirk Schadendorf, MD, discusses demographics, prior therapies and reasons for cemiplimab treatment for CSCC, and more.
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
PIK3CA mutations in breast cancer can be accurately detected using ctDNA, according to analysis data presented at the ESMO 2020 Virtual Congress.
Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma…
Data presented at the virtual ESMO Congress support the use of ASCT in patients with HIV-related lymphoma.
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Stay in the know.
OncNet Newsletter